Jan 9, 2009 - NovaBay Pharmaceuticals, Inc reports that the United States Patent and Trademark Office has approved the issuance of U.S. Patent No. 7,462,361 to NovaBay for novel Aganocide compounds including its current lead compound, NVC-422 (N,N-dichloro-2,2-dimethyltaurine). The patent will expire on April 24, 2026.
The details can be read here.
No comments:
Post a Comment